July 15, 2004

Lilly Announces Senior Leadership Changes

July 15, 2004

Lechleiter to Assume Added Responsibility of U.S. Operations; Santini to Head Corporate Strategy and Policy

Eli Lilly and Company (NYSE: LLY) today announced changes in responsibilities in its senior leadership team. Gino Santini has been named senior vice president for corporate strategy and policy, strengthening Lilly's emphasis on critical issues such as pricing and access to medicines. John C. Lechleiter, Ph.D., executive vice president of pharmaceutical operations, will assume responsibility for the company's U.S. operations. Both Santini and Lechleiter remain on Lilly's corporate policy committee, and both report directly to Sidney Taurel, Lilly chairman, president and chief executive officer.

In his new role, Santini will have responsibility for corporate strategy, business development, alliance management, corporate affairs, and a newly created office of access and pricing.

"This move underscores the increasing importance of issues related to the image of our company and industry along with key strategic concerns," said Taurel. "It is critical that we plan carefully as we address a demanding external environment and prepare for several patent expirations early in the next decade. Among the important challenges for Gino and his team are matters of pricing, reimbursement, and access and ensuring the success of our partnerships.

"Gino brings a unique set of skills and experiences to all these tasks," Taurel continued. "We will benefit significantly from not only his leadership in and knowledge of the U.S. market, but also from his vast global experience.

"Gino has led the U.S. affiliate since 1999 through a period of enormous change," Taurel said. "That includes steering the affiliate through the patent expiration of Prozac and the enormous growth related to the seven new product launches we've had during that time."

Santini joined Lilly in 1983 and has held various positions in affiliates around the world as well as in corporate strategy and business development. He was also president of Lilly's women's health business before heading up Lilly's U.S. operations beginning in 1999.

Lechleiter's role, which currently encompasses pharmaceutical product development as well as pharmaceutical operations, will now include the added direct responsibility of Lilly's U.S. pharmaceutical business.

Taurel commented, "Our U.S. business is critically important to Lilly's ongoing success. John's strong leadership and deep experience will make for a seamless transition during this very exciting time. His direct involvement with U.S. operations will ensure that we maintain good connectivity with other geographies as well as with our global product teams."

Lechleiter joined Lilly in 1979, and his experiences include roles in pharmaceutical product development, project management and regulatory affairs. He has been the head of pharmaceutical products since 1998. He was promoted to executive vice president of pharmaceutical operations and corporate development in 2001 and assumed the role of executive vice president of pharmaceutical operations in 2003.

About Eli Lilly and Company

Lilly, a leading innovation-driven corporation, is developing a growing portfolio of first-in-class and best-in-class pharmaceutical products by applying the latest research from its own worldwide laboratories and from collaborations with eminent scientific organizations. Headquartered in Indianapolis, Ind., Lilly provides answers - through medicines and information - for some of the world's most urgent medical needs. Additional information about Lilly is available at www.lilly.com.

Gino Santini, New Senior Vice President for Corporate Strategy and Policy

John C. Lechleiter, Ph.D., Executive Vice President of Pharmaceutical Operations